Insulin sensitizers are anti-diabetic drugs which help to reduce blood sugar levels by increasing the body's sensitivity to insulin. They are commonly used to treat patients with type 2 diabetes by improving glucose metabolism and utilization of glucose by cells. Insulin sensitizers help overcome insulin resistance which is a major contributing factor for diabetes. Due to its unique mechanism of action to improve glycemic control, insulin sensitizers are gaining widespread acceptance in the management of diabetes.
The global Insulin Sensitizers Market is estimated to be valued at US$ 15.09 Billion in 2023 and is expected to exhibit a CAGR of 4.3% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The prevalence of diabetes has been increasing at an alarming rate globally mainly due to obesity, sedentary lifestyle and unhealthy dietary patterns. According to International Diabetes Federation, around 537 million adults were living with diabetes in 2021 globally and this number is projected to rise to 643 million by 2030 and 783 million by 2045.Increase in diabetes patient pool is the major factor augmenting the growth of insulin sensitizers market. Insulin sensitizers help improve glycemic control significantly and reduce the risk of diabetes related complications. Hence, they are gaining widespread adoption for effective glycemic management in diabetes patients. Technological advancements in development of novel insulin sensitizers with better efficacy and safety is another key trend fueling the market growth over the forecast period.
Segment Analysis
The global insulin sensitizers market is dominated by thiazolidinedione sub segment. This sub segment accounts for more than 60% share of the total market owing to its high efficacy in reducing insulin resistance by increasing insulin sensitivity in peripheral tissues such as muscle and fat. Insulin sensitizing agents helps in lowering blood sugar levels by enhancing insulin sensitivity which helps in better glycemic control.
Key Takeaways
The Global Insulin Sensitizers Market Demand is expected to witness high growth over the forecast period of 2023-2030. With increasing prevalence of diabetes worldwide, insulin sensitizers have gained significant traction as an important treatment option owing to their glycemic control capabilities. The global Insulin Sensitizers Market is estimated to be valued at US$ 15.09 Billion in 2023 and is expected to exhibit a CAGR of 4.3% over the forecast period 2023 to 2030.
Regional analysis: Region wise, North America region currently dominates the global insulin sensitizers market owing to growing prevalence of diabetes and obesity in the region. However, Asia Pacific region is expected to witness fastest growth over the coming years attributed to rising healthcare expenditure and increasing population with diabetic population in major countries like India and China.
Key players: Key players operating in the insulin sensitizers market are ScarAway, Thrive Aesthetics MN, HRA Pharma, MARLO. ScarAway is the global leader followed by Thrive Aesthetics MN owing to its diversified product portfolio addressing different needs of diabetic population. HRA Pharma and MARLO also have strong presence across various countries and are focusing on new product launches and geographical expansion to further strengthen their position in the global market.
Explore more information on this topic, Please visit-
https://www.marketwebjournal.com/insulin-sensitizers-market-growth-and-trnds-analysis-share-size-demand-forecast-2/
Comments
0 comment